Dense breast tissue creates a significant blind spot in routine cancer screening, affecting nearly half of women over 40 and potentially masking life-threatening malignancies on standard mammograms. This screening challenge has prompted federal legislation requiring explicit patient notification about density-related detection limitations, fundamentally changing how millions of women approach breast health monitoring. The core challenge lies in mammography's reduced sensitivity when dense fibrous and glandular tissue obscures tumor visibility, while simultaneously elevating cancer risk by 1.5 to 2-fold compared to fatty breast composition. Digital breast tomosynthesis offers modest improvements over traditional 2D imaging, yet substantial detection gaps persist in the densest tissue categories. Emerging supplemental modalities including MRI, whole-breast ultrasound, contrast-enhanced mammography, and molecular breast imaging demonstrate superior detection capabilities in dense tissue environments. However, these advanced techniques introduce trade-offs including higher false-positive rates, increased costs, and procedural complexity that complicate screening decisions for average-risk populations. The expanding insurance coverage for supplemental imaging reflects growing recognition of this screening gap, yet creates new dilemmas for both patients and clinicians navigating risk-benefit calculations. Without clear consensus guidelines for average-risk women with dense breasts, clinical decision-making becomes highly individualized, requiring sophisticated risk stratification beyond traditional population-based screening protocols. This evolving landscape represents a shift from one-size-fits-all mammography toward personalized screening approaches that account for tissue composition, individual risk factors, and patient preferences in optimizing early detection while minimizing overdiagnosis and anxiety.